R&D Top 30: A look at R&D investments in the Netherlands


New Approach: Recognizing International Players in Local R&D

For the 2024 edition, the criteria have shifted to include R&D activities conducted in the Netherlands, regardless of a company’s headquarters location. This acknowledges the contributions of global companies, such as Airbus and Johnson & Johnson, whose Dutch operations significantly advance technology and knowledge.

Top Performers and Notable Contributors

Once again, ASML leads the list with €2.8 billion spent on R&D in the Netherlands in 2023, maintaining its position as the dominant force in semiconductor development. Other companies, including Philips, Booking Holdings, and Johnson & Johnson, also demonstrate firm R&D commitments. While Johnson & Johnsonranks fifth in Dutch spending, its global R&D efforts far surpass those of other companies on the list, reaching €11.1 billion.

Leiden Bio Science Park and Its Role in Research

Situated in a region known for fostering innovation, Leiden Bio Science Park is home to both global leaders like Johnson & Johnson and emerging biotech ventures. This environment encourages collaboration across industries, particularly in biotechnology, healthcare, and aerospace.

Shifting Trends in R&D Investment

The R&D Top 30 reflects the evolving priorities of businesses operating in the Netherlands. The growth in sectors like digital transformation and biotechnology underscores the importance of a strong research foundation. Companies like Airbus Netherlands and Johnson & Johnson exemplify how local investments contribute to global challenges.

The return of the R&D Top 30 provides a renewed opportunity to assess and celebrate the R&D activity shaping the Netherlands. For those curious about the complete list, the 2024 rankings reveal the breadth and depth of research taking place across industries.


  • SpectaCell raises €6 million to accelerate drug development

    For the Leiden Bio Science Park, it is great to see SpectaCell connecting its technology with the biotech ecosystem here in Leiden. SpectaCell will combine its technology development and cell analysis in Ghent with further validation and application within the…

  • LUMC opens dedicated CAR-T department

    Leiden University Medical Center (LUMC) has opened a dedicated department for CAR-T cell therapy, bringing care, research and expertise in this rapidly developing field together in one place. The new department, officially opened on 24 September, marks another step in…